Payment overview · 2025
General Payments
$456.46
18 reported records · 9 companies
Healthcare provider profile · identity verified
Paul Anthony Monaco, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HAMDEN, CT · NPI 1366436537
Verified facts
What the public records show
CMS Open Payments records show Paul Anthony Monaco, M.D. received $456.46 in general payments during 2025 across 18 reported records.
Janssen Biotech, Inc. accounted for 25.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 467 claims for Eliquis by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $114.81 | 25.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $79.56 | 17.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.35 | 13.9% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.66 | 12.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.11 | 10.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $27.12 | 5.9% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $26.81 | 5.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.79 | 4.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.25 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $456.46 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $114.81 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $79.56 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $58.79 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $55.66 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.35 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $47.11 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.89 | 2 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $27.12 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $26.81 | 1 | 2025 |
Source payment records
|
|||||
| TAKHZYRO Normalized: takhzyro |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 103 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 20 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
467 | 59 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
126 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 810 | 204 |
| Trazodone Hcl | Trazodone Hcl | 555 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 505 | 115 |
| Eliquis | Apixaban | 467 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 418 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 311 | 84 |
| Mirtazapine | Mirtazapine | 294 | 42 |
| Sertraline Hcl | Sertraline Hcl | 283 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 264 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 251 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 251 | 61 |
| Furosemide | Furosemide | 244 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 241 | 73 |
| Losartan Potassium | Losartan Potassium | 238 | 66 |
| Potassium Chloride | Potassium Chloride | 232 | 34 |
| Lisinopril | Lisinopril | 231 | 68 |
| Metformin Hcl | Metformin Hcl | 231 | 61 |
| Gabapentin | Gabapentin | 209 | 49 |
| Famotidine | Famotidine | 201 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 172 | 34 |
| Levetiracetam | Levetiracetam | 149 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 148 | 46 |
| Donepezil Hcl | Donepezil Hcl | 143 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 136 | 15 |
| Xarelto | Rivaroxaban | 126 | 18 |
| Olanzapine | Olanzapine | 121 | 11 |
| Memantine Hcl | Memantine Hcl | 116 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 29 |
| Allopurinol | Allopurinol | 105 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 21 |
| Carvedilol | Carvedilol | 103 | 24 |
| Jardiance | Empagliflozin | 103 | 20 |
| Montelukast Sodium | Montelukast Sodium | 98 | 26 |
| Omeprazole | Omeprazole | 97 | 31 |
| Risperidone | Risperidone | 95 | 14 |
| Ezetimibe | Ezetimibe | 91 | 27 |
| Latanoprost | Latanoprost | 90 | 14 |
| Alprazolam | Alprazolam | 85 | 23 |
| Finasteride | Finasteride | 85 | 19 |
| Lamotrigine | Lamotrigine | 85 | suppressed |
| Ozempic | Semaglutide | 85 | 13 |
| Divalproex Sodium | Divalproex Sodium | 82 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 21 |
| Farxiga | Dapagliflozin Propanediol | 70 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 37 |
| Tradjenta | Linagliptin | 68 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 13 |
| Alendronate Sodium | Alendronate Sodium | 67 | 21 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 65 | 17 |
| Myrbetriq | Mirabegron | 64 | suppressed |
| Januvia | Sitagliptin Phosphate | 62 | suppressed |
| Spironolactone | Spironolactone | 60 | 17 |
| Simvastatin | Simvastatin | 54 | 17 |
| Aripiprazole | Aripiprazole | 52 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 15 |
| Nyamyc | Nystatin | 51 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 11 |
| Prednisone | Prednisone | 49 | 19 |
| Baclofen | Baclofen | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Lorazepam | Lorazepam | 46 | 20 |
| Atenolol | Atenolol | 45 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 42 | 12 |
| Meloxicam | Meloxicam | 42 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 40 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Bumetanide | Bumetanide | 39 | suppressed |
| Torsemide | Torsemide | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 12 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Valsartan | Valsartan | 36 | 13 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Xifaxan | Rifaximin | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Rivastigmine | Rivastigmine | 34 | suppressed |
| Tirosint | Levothyroxine Sodium | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Cephalexin | Cephalexin | 33 | 17 |
| Diltiazem 24hr Er | Diltiazem Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 24 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 33 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 31 | 22 |
| Brimonidine Tartrate | Brimonidine Tartrate | 30 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Lopressor | Metoprolol Tartrate | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 20 |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Lactulose | Lactulose | 26 | 15 |
| Nystatin | Nystatin | 26 | 14 |
| Clozapine | Clozapine | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 15 |
| Novolog | Insulin Aspart | 24 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 23 | 16 |
| Methimazole | Methimazole | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 14 |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Lubiprostone | Lubiprostone | 20 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 20 | 13 |
| Anastrozole | Anastrozole | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | 13 |
| Topiramate | Topiramate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 13 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 15 | 13 |
| Risperidone Odt | Risperidone | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Azathioprine | Azathioprine | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Levetiracetam Er | Levetiracetam | 14 | suppressed |
| Mesalamine | Mesalamine | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $456.46 · 18 records | Janssen Biotech, Inc. | EVENITY, JARDIANCE, MOUNJARO, ORENCIA, PROLIA, PURIFIED CORTROPHIN GEL, TAKHZYRO, TREMFYA, UNITHROID, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error